Navigation Links
All-Time High in Q Orders for Wound Management Technologies, Inc.
Date:10/6/2010

FORT WORTH, Texas, Oct. 6 /PRNewswire/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its subsidiary Wound Care Innovations, LLC has added the company's first pharmacy client to its rapidly growing list of customers.  Lewis Hall, Inc. of Fort Worth, TX is an independent pharmacy group that has several locations and 30 years experience in wound care, long term care and specialty compounded products for dermatologic use.  Lewis Hall, company president, was quoted as saying, "We are genuinely excited about having Cellerate RX® as part of our product line. It has had such tremendous outcomes that we believe our customers will find it to be one of the best wound healing products in the market."

This order punctuates a string of recent successes for WCI in the 3rd Quarter resulting in the company having the best sales order quarter in its history, with one order for over $300,000 of products that will be shipped during the 4th quarter of 2010. WCI continues to surge ahead in the execution of its growth strategy highlighted by its expansion in the South African and Central American markets as well as in the government sector through its addition of Veterans Health Administration facilities in Texas and Florida as announced last month.

Ronald D. Mathis, Senior Vice President of Marketing and Sales said, "We understand that sales growth rarely happens at the pace that everyone would prefer. However, what we are seeing here is the focused execution of a highly developed plan that has the opportunity to yield phenomenal results for both Wound Management Technologies and its shareholders."

WNDM is filing a Form 8k today about recent company progress along with a presentation being made on October 7, 2010 to the investment community. 

For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com

About Wound Care Innovations, LLC

Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM.ob - News) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products.  For more information on Cellerate RX®, please visit the WCI web site at http://www.celleraterx.com/ .

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, Cellerate RX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes.  Over the past 2 years Wound Management has focused on developing evidenced-based studies on Cellerate RX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage.  More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com, and http://www.secureehealth.com.

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

For Further Information:

Shareholder Relations-Communications (817)820-7077


'/>"/>
SOURCE Wound Management Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Depression and Cognitive Disorders: at the Onset of Alzheimers Disease
2. A brief explanation of Dopamine-Beta-hydroxylase (DBH) - SymPath(R) : In Vitro Diagnostic Test to distinguish anxious disorders from depressive disorders
3. FDA Orders Halt to Marketing of Unapproved Single-Ingredient Oral Colchicine
4. ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program, Confirming Microplasmins Potential to Transform the Treatment of Retinal Disorders
5. Reportlinker Adds Urological Disorders Therapeutics to 2016 - Increasing Awareness and Aging Population will Drive the Benign Prostatic Hyperplasia and Urinary Incontinence Markets
6. New Report World Dermatology Market (Drugs, Therapeutic Segments and Disorders) (2010 to 2015) Published By MarketsandMarkets
7. Unprecedented Donation Made by Mrs. Lily Safra to the Institute for Brain and Spinal Cord Disorders in Paris
8. Ambry Genetics Introduces AmbryScreen(TM), a Genetic Test Screening for Some of the Most Common and Severe Genetic Disorders Affecting Newborns.
9. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
10. Gamma Knife Users Share Latest Advances for Treating Cancer, Other Brain Disorders at Society Meeting in Greece
11. Ligon Discovery and Lycera Collaborate to Develop First-in-Class Drugs for Immune Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MONMOUTH JUNCTION, N.J. , Dec. 2, 2016 /PRNewswire/ ... critical care immunotherapy leader commercializing its European Union approved ... in critically-ill and cardiac surgery patients worldwide, announced that ... present at the 9th Annual LD Micro Main ... 8 th , 2016 at the Luxe Sunset Boulevard ...
(Date:12/2/2016)... LYME, Conn. , Dec. 1, 2016  Today, ... has announced the honor of being selected as winners ... include: Simpson Healthcare Executives Website at the PLATINUM level, ... Conversations Training Module at the GOLD Level, and our ... At Simpson Healthcare Executives, we are excited ...
(Date:12/2/2016)... YORK , December 2, 2016 ... of its past losses following Trump,s victory early in ... potential, and fund managers are now predicting an uptick ... at four equities to see how they have fared ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... launch of its 60-day free trial program for all of the company’s desktop ... offer a truly hassle free experience. , FlexiSpot’s unique desktop risers use an ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
(Date:12/2/2016)... ... December 02, 2016 , ... With the number of pain management programs available ... must find the one that works for them. When an inventor from Suisun City, ... worked and decided to share it with others. , He developed a prototype for ...
(Date:12/2/2016)... ... December 02, 2016 , ... Dr. Raffi Hovsepian, a leading ... the 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The ... education, experience, and professional associations. , One the most frequently honored surgeons ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to announce ... covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping patients ... life 6 years in the last 3 decades,” says Dr. Valentine Fuster, a ...
Breaking Medicine News(10 mins):